BIO:ON Insight EN #4 · Jun 16, 2026 · Biosimilar · Bispecific Antibody · New Target

Copy, combine, or go where no drug has gone:
three ways to make a new medicine

A first-to-market biosimilar, a two-in-one antibody for lung cancer, and a first attempt at a target nobody had drugged. This week's three stories, read for your career.

Putting this week's news together, one question came to mind: which direction is drug innovation actually heading? On one side, a biosimilar makes a proven drug cheaper. In the middle, a bispecific antibody ties two known targets into one molecule. And at the far end, a company takes its first shot at a target no one had ever turned into a drug. Three very different routes, all trying to reach patients.

— Editor · MSc Biotechnology & Pharmaceutical Management

🔤 Word of the Week

Bispecific Antibody (PD-L1×VEGF)

The mechanism behind this week's BioNTech and BMS story (Story 2)

A normal antibody grabs one target. A bispecific antibody has two different "claws" on one molecule, so it can grab two targets at once. This week's pumitamig binds the immune checkpoint protein PD-L1 and the blood-vessel growth factor VEGF-A. It releases the immune brake (PD-L1) and tidies up tumour blood vessels (VEGF-A), effectively two drugs in one.

💡 Analogy: If a regular antibody is one hand holding one door handle, a bispecific is two hands on two handles at once. One hand releases the PD-L1 door (the brake on immune cells), the other sorts out the VEGF-A door (the tangled tumour blood vessels). One molecule doing two jobs aims to stack the effects and simplify treatment.

Arm 1: PD-L1 — release the immune brake

Tumours display PD-L1 to switch off attacking T cells. Blocking it lets immune cells go back on the attack. It's the same axis drugs like Keytruda target.

Arm 2: VEGF-A — normalise tumour vessels

Tumours use VEGF-A to build messy blood vessels that keep immune cells out. Blocking it tidies up the vessels so immune cells can get in. Together: brake off, and a clear road in.

📰 This Week's Top 3 Stories

STORY 1 · REGULATORY APPROVAL · BIOSIMILAR

Bio-Thera Wins FDA Approval for the First Biosimilars to Simponi and Simponi Aria

Bio-Thera Solutions press release · US partner Accord BioPharma | Launched May 18, 2026

Key Facts

The FDA approved two golimumab biosimilars developed by Bio-Thera Solutions. They're the first biosimilars referencing J&J's Simponi (subcutaneous) and Simponi Aria (intravenous). Golimumab is an anti-TNFα monoclonal antibody used in rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis and ulcerative colitis. Accord BioPharma handles US commercialisation and launched on May 18, 2026.

Plain-English Breakdown 🧩

A biosimilar is a copy of an off-patent biologic that's been shown to be just as safe and effective. Unlike small-molecule generics, biologics are made in living cells, so a biosimilar isn't identical, but the FDA has judged there's no clinically meaningful difference. The key point: Simponi had no biosimilar competition until now. This is the first challenger, which is where lower prices and wider access start.

🌍 Global Lens

Bio-Thera is a Chinese company, and this approval is part of a bigger shift: Asian biosimilar makers such as Celltrion and Samsung Bioepis are now major suppliers to Western markets. Europe usually adopts biosimilars faster than the US, because national tenders and hospital purchasing push prices down quickly, so the US launch will be an interesting test of how fast a first challenger can take share.

Why it matters for your career: Biosimilar companies hire heavily in regulatory, manufacturing and market access. Knowing that first-mover advantage and supply matter as much as the science goes a long way in an interview.

📌 The first biosimilars to both Simponi and Simponi Aria, commercialised in the US by Accord BioPharma from May 18, 2026. — Bio-Thera Solutions press release summary

STORY 2 · CLINICAL · ONCOLOGY

BioNTech and BMS's PD-L1×VEGF Bispecific pumitamig Shows Strong Responses in First-Line Lung Cancer

BioNTech (Nasdaq: BNTX) · Bristol Myers Squibb (NYSE: BMY) press release | 2026

Key Facts

BioNTech and Bristol Myers Squibb (BMS) released interim Phase 2 data from the global Phase 2/3 ROSETTA Lung-02 trial in previously untreated advanced non-small cell lung cancer (NSCLC). Patients received pumitamig, a bispecific that hits PD-L1 and VEGF-A, plus chemotherapy. The companies reported encouraging anti-tumour activity and high response rates in both squamous and non-squamous NSCLC, across all PD-L1 expression levels. Specific response and survival numbers haven't been released yet.

Plain-English Breakdown 🧩

The usual first-line treatment for lung cancer is an immunotherapy (PD-1/PD-L1) plus chemotherapy. pumitamig adds VEGF blocking in the same molecule. Patients with low PD-L1 expression usually get less benefit from immunotherapy, so responses across all expression levels suggest it could help a wider group. It's still interim Phase 2, though, with Phase 3 to come. The Word of the Week above explains the mechanism.

🌍 Global Lens

The PD-(L)1×VEGF idea took off in China. Akeso's ivonescimab showed it could work first, and BioNTech's own molecule came from Biotheus, a Chinese biotech it bought. So this is a Western pairing competing on a mechanism China pioneered, and Akeso's US partner Summit is running the same race. Where the first global approvals land will say a lot about who leads oncology innovation now.

Why it matters for your career: Clinical and medical teams want people who can be excited about a result and still say clearly that an interim readout isn't proof. That balance is harder than it sounds.

📌 pumitamig plus chemotherapy showed high response rates and encouraging anti-tumour activity in squamous and non-squamous NSCLC and across PD-L1 expression levels. — BioNTech · BMS ROSETTA Lung-02 interim summary

STORY 3 · DRUG DEVELOPMENT · NEW TARGET

Orion Reports First-in-Human Results for ODM-212, an Oral pan-TEAD Inhibitor

Orion Pharma (HEL: ORNBV) press release · TEADES Phase 1/2 | 2026

Key Facts

Orion Pharma reported the first Phase 1 results for ODM-212 from its ongoing first-in-human Phase 1/2 TEADES trial in patients with advanced solid tumours. ODM-212 is an oral pan-TEAD inhibitor. TEAD proteins are the key transcription factors of the Hippo pathway; together with YAP/TAZ they drive tumour growth and drug resistance, and they've long been considered hard to drug. ODM-212 blocks the whole TEAD family at once. Specific efficacy and safety numbers haven't been released yet.

Plain-English Breakdown 🧩

Unlike a biosimilar (copying a proven drug) or a bispecific (combining proven targets), ODM-212 is a first attempt at a target nobody had turned into a drug. Programmes like this have lower odds of success, but when they work they open a market with no competitors: high risk, high reward. "First Phase 1 results" means they've only just started checking whether it can be given safely to people.

🌍 Global Lens

Orion is Finnish, which is a nice reminder that first-in-class science doesn't only come from US biotechs or the biggest pharma companies. Mid-sized European firms can't outspend the giants, so they often pick hard, unfashionable targets where being early matters more than being big. Several other companies are also chasing TEAD, so this is a global race that's barely started.

Why it matters for your career: Early development teams value people who can explain why a target matters without overselling a first-in-human readout.

📌 First Phase 1 results from the first-in-human TEADES Phase 1/2 trial of oral pan-TEAD inhibitor ODM-212 in advanced solid tumours. — Orion Pharma press release summary

🔬 This Week's Deep Dive

Deep Dive · The Innovation Spectrum

Copy, combine, create —
which road does a new drug take, and at what risk?

① Three roads in one week

This week's stories lay out the whole spectrum of drug innovation. Bio-Thera entered the market by copying a proven drug more cheaply, already approved and launched. BioNTech and BMS combined two proven targets (PD-L1 and VEGF) into one molecule and produced Phase 2 lung cancer data. Orion tried to create something new, taking its first shot at pan-TEAD. The further you move along that line, the more both the risk and the potential reward grow.

② Three companies, three routes

Bio-Thera	BioNTech · BMS	Orion
Type of Innovation
Copy — golimumab biosimilar	Combine — PD-L1×VEGF bispecific	Create — oral pan-TEAD (first-in-class)
Stage
Approved and launched	Interim Phase 2 of a Phase 2/3	First Phase 1 results
Risk Level
Lowest — main risk is price competition	Medium — Phase 3 still to come	Highest — efficacy unknown

③ Why the spectrum matters

There's no single right road. Each creates different value and carries different risk. Biosimilars are fast and stable but face fierce price competition. Bispecifics combine proven targets cleverly, chasing both a good chance of success and differentiation. First-in-class drugs are the riskiest, but if they work they open a market with no rivals. A healthy industry needs all three. So before ranking a piece of news, place it on the spectrum first.

④ Career takeaway: every road needs different people

✓ Skill to build

Each road runs on different skills. Biosimilars need CMC, manufacturing, regulatory and pricing expertise. Bispecifics lean on protein engineering, translational research and clinical development. New targets need target discovery and early (Phase 1) clinical work. Being able to look at a drug and say "this is where it sits, and these are the skills behind it" is one of the most useful things you can bring to career planning, and to an interview.

⚠ Trap

Getting swept up by words like "first-in-class" and forgetting the stage. A first Phase 1 result like ODM-212's is a possibility, not proof. The opposite trap is dismissing biosimilars as "just copies." Read the clinical stage, data maturity and type of innovation together.

💡 Editor's Insight

What I found most interesting this week is that the stock reactions followed how mature the data was, not how new the idea was. The newest attempt, the new target, was the quietest. So the next time you see "first-in-class," check which phase it's in before getting excited. That habit alone keeps headlines from pushing you around. See you next issue. 🙏

📊 Numbers of the Week

1st

Biosimilars to Simponi and Simponi Aria

Bio-Thera's golimumab biosimilars, the first for both reference products. (FDA approval)

Targets in one molecule (PD-L1×VEGF-A)

What pumitamig binds at once, with high responses across squamous, non-squamous and all PD-L1 levels. (BioNTech · BMS)

Phase 1

ODM-212 (oral pan-TEAD, first-in-class)

First results from the first-in-human TEADES Phase 1/2 in advanced solid tumours. (Orion)

📈 3 Stocks That Moved This Week

Direction and catalyst, sketched — not exact prices. Check a real chart for that.

BioNTech

NASDAQ: BNTX

▲ Strong

Positive interim Phase 2 lung cancer data for pumitamig lifted sentiment, as investors bought into the combine strategy. Hiring signal: a bispecific heading into Phase 3 usually means more clinical operations and translational roles in oncology. (Directional sketch.)

Bristol Myers Squibb

NYSE: BMY

▲ Edging up

Benefited as pumitamig's partner, but as a large cap it moved more gently than BioNTech. (Directional sketch.)

Orion Pharma

HEL: ORNBV

≈ Flat

With ODM-212 at first Phase 1 results, the market is waiting and seeing. Orion's larger businesses (Parkinson's and prostate cancer) mean a new-target story barely moves the stock. (Directional sketch.)

🔎 Why this pattern

The size of each reaction matched how far along the data was. BioNTech, with clinical data, rose clearly; its large partner BMS edged up; Orion, at first Phase 1 results, barely moved. Same week of good news, but the market priced it by data maturity. (All directional sketches — check a real chart for exact prices.)

🎯 Roles to Watch This Week

Teams worth watching based on this issue's news — not live job postings, so check each company's careers page for what's actually open.

Bio-Thera / Accord BioPharma — Market Access / Supply Chain

Why now: the first biosimilar launch against a reference product is won through payer contracts and reliable supply. Look under "Market Access," "Trade" or "Supply Chain."

BioNTech / BMS — Clinical Operations (Oncology)

Why now: moving ROSETTA Lung-02 into its Phase 3 portion needs trial managers and clinical scientists across many sites. Look under "Clinical Operations" or "Clinical Science."

Orion — Early Clinical Development / Translational Oncology

Why now: dose-finding and biomarker work in Hippo-pathway tumours is where a first-in-class programme lives or dies. Look under "Early Development" or "Translational."

🗓️ Dates to Watch

When / Event	Why It Matters
Autumn 2026 (expected) ESMO Congress 2026 — latest lung cancer immunotherapy data	Where more data on PD-L1×VEGF bispecifics like pumitamig, and the competitive picture, is likely to appear.
H2 2026 ROSETTA Lung-02 — follow-up Phase 2/3 data	Formal response and survival numbers, and progress into Phase 3, are what matter after the interim readout.
Ongoing Golimumab biosimilar US uptake · TEADES dose selection (RP2D)	Track Accord's market share after launch, and ODM-212's recommended Phase 2 dose and early efficacy signals.

When / Event

Why It Matters

Autumn 2026 (expected)

ESMO Congress 2026 — latest lung cancer immunotherapy data

Where more data on PD-L1×VEGF bispecifics like pumitamig, and the competitive picture, is likely to appear.

H2 2026

ROSETTA Lung-02 — follow-up Phase 2/3 data

Formal response and survival numbers, and progress into Phase 3, are what matter after the interim readout.

Ongoing

Golimumab biosimilar US uptake · TEADES dose selection (RP2D)

Track Accord's market share after launch, and ODM-212's recommended Phase 2 dose and early efficacy signals.

Copy, combine, create: this week put all three roads to a new medicine on one page. None is better than the others; they just carry different risks on the way to the same patients. Next issue, we'll keep placing each story on the spectrum. 🙏

How was this issue?

👍 Loved it 🤔 Could be better

Found this useful? Share it with a classmate. 📤

Share the subscribe link

Follow along → @bio.on_insight

🔗 Sources

① Bio-Thera wins FDA approval for golimumab biosimilars — Bio-Thera Solutions press release ② BioNTech and BMS report interim Phase 2 data for pumitamig in ROSETTA Lung-02 — BioNTech / BMS press release ③ Orion Pharma reports first Phase 1 results for oral pan-TEAD inhibitor ODM-212 (TEADES) — Orion press release

Global biotech & pharma news, translated into career signal —
every Tuesday, for students and early-career professionals.

🌐 Read on the web · past issues archive → bioon-website.vercel.app

Copy, combine, or go where no drug has gone:three ways to make a new medicine

Copy, combine, or go where no drug has gone:
three ways to make a new medicine